Director, Government Pricing & Contracting Analytics

The Director, Market Access & Government Pricing Analytics is responsible for oversight of all government pricing calculations. He/she will work closely with cross functional teams to evaluate impacts to government pricing and will participate in analyses to support market access channel strategies, including managing bottoms up model and gross-to-net forecast. This individual is expected to establish and maintain collaborative working relationships with internal/external contacts and peers to ensure effective communication and a high-level of customer service.

Responsibilities

• Oversight of all government pricing calculations, analyses, and submissions, including Average Selling Price (ASP), Average Manufacturer’s Price (AMP), Best Price (BP), Public Health Service (PHS)/340B pricing, Non-Federal Average Manufacturer’s Price (Non-FAMP), Federal Ceiling Price (FCP), and Federal Supply Schedule prices (FSS) in accordance with the Medicaid Drug Rebate Program and all Federal Program Guidelines
• Partner with key stakeholders to ensure timely and accurate filing of all government reporting to avoid significant monetary penalties assessed by various government agencies for late or inaccurate reporting
• Represent Market Access on cross-functional teams to evaluate issues impacting government pricing and prepare analyses to understand the impact of new pricing and contracting strategies on Government Pricing calculations
• Ensure compliance with laws governing government programs, including Medicaid, are within written policies, procedures, and standards of conduct
• Maintains an understanding of the marketplace and changes that may impact government price reporting and government channel strategy.
• Responsible for maintenance of documentation and procedures regarding government pricing, as well as internal and external audits
• Inform brand forecasts including account and channel-level gross to net projections, Medicaid Unit forecasts, and government impact of proposed strategy changes (CPI penalties, Medicaid Mandated Rebate, BP)
• Responsible for managing bottoms up model for in-line and launch products, including forecasting brand gross-to-net deductions
• Provide GPO contracting support, including pre and post deal analyses
• Participate in analyses to understand impact of market events on government price reporting and development of channel strategies (i.e. assessment of pipeline products coverage, analysis of impact of payer coverage policies, and provider/channel economics)
• Proactively seeks and recommends enhancements and improvements in Market Access processes, including recommending resources, new approaches, negotiating agreeable solutions, or involving next-level management as needed.
• Responsible for shaping and monitoring the evolution of the market access and government policy landscape in the short, near, and long-term.

Skills/Knowledge

• Bachelor’s degree; preferably in a relevant field (Marketing, Science, Economics, finance or related field)
• 5 years of related healthcare business experience in pharmaceutical industry
• In depth understanding in Government Pricing, Market Access and Healthcare delivery.
• Analytical skills including problem solving, forecasting, contract development and financial modeling.
• Demonstrated negotiation and relationship building skills.
• Demonstrated ability to manage multiple priorities
• Strong oral and written communication skills, including a strong focus on customer service

Base Salary Range of $213,000-$258,000.  Menarini Stemline offers generous compensation and benefits packages,  including Short- and Long-Term Incentive Programs,  Fidelity 401(k) (with 6% company match), Anthem Premier PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.

Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.

About us:

Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions.

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.

Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.